Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Monterrey
Clinical trial register · Mexico

Clinical Trials in Monterrey, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1585 matching records held by the registry are in this view. Synced 12 Oct 2026, 03:18 UTC
1585
Studies in scope
all four open statuses
715
Recruiting now
open to new participants
254
Lead sponsors
across recruiting studies
Top sites
Mexico City 17 Monterrey 15 Guadalajara 14 Mérida 8 Chihuahua City 8
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Monterrey

15 of 1585 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
Novartis Pharmaceuticals
Phase 3
220
Monterrey
2025-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Monterrey, Culiacán, Durango
2025-03-20
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Monterrey
2024-10-29
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Monterrey, San Luis Potosí City
2024-10-24
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Chihuahua City, Guadalajara, Mexico City, Monterrey
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Monterrey
2024-09-04
Recruiting
Novartis Pharmaceuticals
Phase 3
1,400
Alc Cuahutemoc, Tlalpan, Monterrey
2024-02-28
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
383
Chihuahua, Barrio Belisario Domínguez Secc, Oaxaca, Aguascalientes, Chihuahua City, Monterrey
2023-07-06
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
León, Actopan, Guadalajara, Gustavo Adolfo Madero, Mexico City, Tlalpan, Cuernavaca, Monterrey
2023-03-09
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Mexico City, Monterrey
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Saltillo, Morelia, Monterrey
2023-02-02
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals
Phase 4
347
Monterrey
2022-08-30
Active, closed
Novartis Pharmaceuticals
Phase 3
452
León, Monterrey, Oaxaca City, Querétaro
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Guadalajara, Mexico City, Monterrey, Tlalnepantla, Mérida, Acapulco, Aguascalientes, Chihuahua City
2021-11-23
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
Novartis Pharmaceuticals
Phase 4
279
Monterrey
2015-03-05
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-mexico/city/monterrey

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,585 studies in total at the last sync on 12 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies with a site in Monterrey that also match the filters currently applied.

How many clinical trials are recruiting in Monterrey?

5 of the 15 studies on this page are recruiting new participants as of the 12 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Monterrey), 15 studies
PhaseStudiesRecruitingShare
Phase 39260%
Phase 23120%
Phase 42113.3%
Phase 1/2116.7%

Most active sponsors

Lead sponsors with the most studies (Monterrey)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals155
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.